How Johnson & Johnson Beat Expectations in Q1
Johnson & Johnson (NYSE: JNJ) has been in the news quite a bit recently. And not for good reasons. The healthcare giant's COVID-19 vaccine is still on pause in the U.S. due to concerns about rare blood clotting issues. A key facility where the vaccine is manufactured has been temporarily shut down while the U.S. Food and Drug Administration (FDA) conducts an inspection.
However, the company recently saw some good news for a change. Johnson & Johnson announced its first-quarter results before the market opened on Tuesday. Here are the highlights from J&J's Q1 update.
Image source: Getty Images.
Source Fool.com
